Articles from Kenvue Inc.

Kenvue Inc. (NYSEKVUE) (“Kenvue”) today announced the Company’s participation in Deutsche Bank’s dbAccess Global Consumer Conference in Paris, France. Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Carlton Lawson, Group President, Europe, Middle East and Africa & Latin America will participate in a fireside chat on Tuesday, June 4, 2024, at 8:45 a.m. Eastern Time / 2:45 p.m. Central European Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be available on the website following the event.

Kenvue Inc. (NYSEKVUE) (“Kenvue”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 182,329,550 shares of its common stock (the “Shares”). Kenvue is not selling any shares of common stock and will not receive any proceeds from the sale of the Shares in the Offering or from the debt-for-equity exchange (as described below).

Kenvue Inc. (NYSEKVUE) (“Kenvue”), today announced financial results for the fiscal first quarter ended March 31, 2024.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the second quarter of $0.20 per share on the Company’s common stock. The second quarter dividend is payable on May 22, 2024 to shareholders of record as of the close of business on May 8, 2024.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the first quarter ending March 31, 2024, before market open on May 7, 2024.

Kenvue Inc. (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will share new data demonstrating how its iconic brands are contributing to the advancement of everyday skin care at the American Academy of Dermatology (AAD) Association Annual Meeting, set for March 8-12 at the San Diego Convention Center in San Diego, California.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced Thibaut Mongon, Chief Executive Officer, and Paul Ruh, Chief Financial Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference in Boca Raton, Florida, on Friday, February 23, 2024, at 10:00 a.m. Eastern Time. A live webcast of the session will be available at investors.kenvue.com and a replay will be available on the same website following the event.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced financial results for the fiscal full year and fourth quarter ended December 31, 2023.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter of $0.20 per share on the Company’s common stock. The first quarter dividend is payable on February 28, 2024 to shareholders of record as of the close of business on February 14, 2024.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023, before market open on February 8, 2024.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced the company’s participation in Morgan Stanley’s Global Consumer & Retail Conference, in New York. Chief Executive Officer and Director, Thibaut Mongon, and Chief Financial Officer, Paul Ruh, will participate in a fireside chat on Wednesday, December 6, 2023 at 11:45 a.m. Eastern Time. A live webcast of the session will be available at https://investors.kenvue.com and a replay will be available on the website following the event.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced financial results for the fiscal third quarter ended October 1, 2023.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the third quarter ending October 1, 2023, before market open on October 26, 2023.

Kenvue Inc. (NYSEKVUE) (“Kenvue”) today announced its separation from Johnson & Johnson, marking its first day as a fully independent company.

Kenvue Inc. (NYSEKVUE) (“Kenvue”) announced that it intends to file a Form S-4 Registration Statement today with the Securities and Exchange Commission (the “SEC”) in connection with Johnson & Johnson’s NYSE: JNJNYSEJNJ)

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the third quarter of 2023 of $0.20 per share on the Company’s common stock.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced financial results for the fiscal second quarter ended July 2, 2023.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its financial results for the second quarter ending July 2, 2023, will be released before market open on July 20, 2023.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced the company’s participation in Deutsche Bank’s dbAccess Global Consumer Conference 2023 in Paris. Chief Executive Officer and Director, Thibaut Mongon, and Chief Financial Officer, Paul Ruh, will participate in a fireside chat on Thursday, June 8, 2023, at 12:30 p.m. Central European Summer Time (6:30 a.m. ET). A live webcast of the session will be available at https://investors.kenvue.com and a replay will be available on the website following the event.

Kenvue Inc. (NYSEKVUE) (“Kenvue”) the world’s largest pure-play consumer health company by revenue, today announced the closing of its initial public offering (“IPO”) of 198,734,444 shares of its common stock at a price to the public of $22.00 per share, including the underwriters’ full exercise of their option to purchase 25,921,884 shares to cover over-allotments. Shares of Kenvue’s common stock began trading on the New York Stock Exchange under the symbol “KVUE” on May 4, 2023.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will begin trading today on the New York Stock Exchange under the ticker symbol “KVUE” in connection with its initial public offering (“IPO”). Chief Executive Officer (“CEO”) and Director, Thibaut Mongon, and members of the Kenvue Leadership Team will celebrate by ringing the Opening Bell.